This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Q2 Sep 2026: revenue 14,863.64 vs 216.51 lakh; PAT 671.39 vs 659.73 lakh, year on year
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved standalone results for the September 2026 quarter: operating revenue was Rs 14,863.64 lakh versus Rs 216.51 lakh a year earlier; PAT was Rs 671.39 lakh versus Rs 659.73 lakh. EBITDA margin rose to 6.0 percent from negative 30.0 percent. The auditor qualified the review over cash accounting for gratuity and leave; the impact was not quantifiable. Manufacturing stopped; operations shifted to IT services and farm produce trading.
Revenue surged, but PAT was nearly flat. The qualified review raises reporting risk, while the new trading-led model raises execution risk.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹148.6 Cr against ₹2.17 Cr a year ago, about 69× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.